In Focus this month:
- Conference on Retroviruses and Opportunistic Infections Presents Globally Important HIV Data (CROI Foundation and International Antiviral Society, Seattle, Washington)
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) presented HIV research findings of global importance, including the success of three oral pre-exposure prophylaxis trials and negative findings from a trial of 1 percent tenofovir gel.
- Making Pre-exposure Prophylaxis Work for At-risk Youth (Journal of the International AIDS Society)
This study found that pre-exposure prophylaxis (PrEP) could offer highly effective, time-limited primary HIV prevention for young key populations, if they had access to health services and were motivated to use PrEP. The authors also identified barriers specific to the under-24-years age group of men who have sex with men, transgender women, sex workers, and people who use drugs.
- Tenofovir-based Pre-exposure Prophylaxis Does Not Reduce HIV Transmission (New England Journal of Medicine)
This study assessed the effect of regimens with oral tenofovir disoproxil fumarate (TDF), oral tenofovir–emtricitabine (TDF-FTC), or 1 percent tenofovir vaginal gel in 5,029 women in South Africa, Uganda, and Zimbabwe. The findings showed that none of the regimens reduced rates of HIV-1 acquisition, and that daily adherence to both oral and vaginal TFV-based formulations was low.